Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression

Clinical Data, Inc. (NASDAQ: CLDA) announced today that the United States Adopted Name Council (USAN) has approved the generic name vilazodone hydrochloride. Vilazodone, if approved, would represent a first-in-class drug for the treatment of depression, due to its novel dual mechanism of action as both a potent and selective serotonin reuptake inhibitor (SSRI) and a partial agonist of the 5-hydroxytryptamine 1a (5-HT1A) receptor. Thus, vilazodone combines first-line therapy for depression with 5-HT1A partial agonism, an accepted adjunctive treatment for depression and a first-line therapy for anxiety disorders. Clinical Data has recently completed the second of two positive Phase III registration studies. Results of these studies will form the basis of a new drug application (NDA) that the Company intends to submit with the U.S. Food and Drug Administration (FDA) by the end of 2009.

CDC Issues Fact Sheet On Oral Sex, HIV Transmission

The CDC has released a fact sheet informing people that there is some risk of transmitting HIV to others through oral sex, even though it is much lower than the risk of transmission from vaginal or anal intercourse, the Lakeland Ledger"s "Robin"s Rx: Medical Blogging in Polk County" reports. According to the CDC, many people believe that oral sex is safe or has no risk of transmitting disease. The CDC fact sheet said that abstaining from any sexual activity or engaging in mutual monogamy where both partners are uninfected are the only ways to completely prevent HIV transmission, but that condoms and other barriers between the mouth and genitals can reduce the risk of transmission through oral sex (Adams, "Robin"s Rx: Medical Blogging in Polk County," Lakeland Ledger, 6/4).

News of the day

Radionuclide Contamination At DOE Sites Addressed By New Research

Five years from now, Lab scientists will be able to better determine how, when and why plutonium moves in soil and groundwater.

Health Insurance

Gene Signature Predicts Good Outcome In Breast Cancer

Researchers have identified a genetic signature that can predict an improved clinical outcome in patients with breast cancer, and which could help in the development of new targeted therapies. By analysing the expression of different genes induced by a specific mutation in a molecule called PIK3CA, a critical part of the pathway commonly deregulated in breast cancer, they found that these genes were correlated with an improved clinical outcome in over 1500 women with the disease. European Society for Medical Oncology

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):